Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Evaluation of OHIP-14 and OSHIP-14 in Patients With Varying Periodontal Disease

NCT07545109 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2025-09-01
Last updated
2026-04-22

Condition(s) studied

Periodontal Disease

Investigational drug(s) / intervention(s)

No Interventions

No Interventions: Participants underwent a comprehensive periodontal examination, including probing pocket depth (PPD), clinical attachment loss (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BOP) assessments. In addition, oral health-related quality of life was evaluated using the OHIP-14 and OShip-14 questionnaires. No therapeutic or pharmacological intervention was applied.

Study summary

This study aims to evaluate periodontal health status and its impact on oral health-related quality of life by combining clinical periodontal parameters with validated patient-reported outcome measures. Periodontal assessments included probing pocket depth (PPD), clinical attachment loss (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BOP). Participants were further classified according to periodontal disease staging and grading. To assess the subjective impact of periodontal conditions on daily life, the Oral Health Impact Profile-14 (OHIP-14) and its shortened version, the Oral Health Impact Profile-14 short form (OShip-14), were administered.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Aged between 18 and 65 years Diagnosed with periodontitis (any stage) Willing to participate in the study and provide informed consent Exclusion Criteria: * Refusal to participate in the study Pregnancy or lactation Use of antibiotics or anti-inflammatory drugs within the last 3 months

Primary outcome measure(s)

  • OSHİP-14 — One-time assessment at enrollment
    OShip-14 is a 14-item short-form questionnaire designed to assess oral health-related quality of life, evaluating the physical, psychological, and social impacts of oral and dental health on daily life.

Trial sites (1)

FacilityCityRegionStatus
Bolu Abant Izzet Baysal University Bolu Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07545109 on ClinicalTrials.gov ↗ ← All trials in Turkey